Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Pembrolizumab +/- Lenvatinib for High Risk Renal Cell Carcinoma
NCT05733715Phase 1Recruiting
- Sponsor
- Abramson Cancer Center
- Start
- May 2023
- Primary completion
- Apr 2028
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in renal cell carcinoma (RCC) comparing Pembrolizumab + Lenvatinib with Pembrolizumab (2 arms). Primary endpoint: Change in frequency of progenitor exhausted CD8 T cells. Started May 2023; status: recruiting.
02
Drugs
pembrolizumablenvatinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT05733715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05733715.